ASC30
AURORA-1
Ascletis Pharma (China) Co · Phase 3 · Recruiting · Enrollment 3003
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| ASC30 Cohort 1 | n/r | n/r | n/r | n/r |
| ASC30 Cohort 2 | n/r | n/r | n/r | n/r |
| ASC30 Cohort 3 | n/r | n/r | n/r | n/r |
| Placebo Cohort 4 | n/r | n/r | n/r | n/r |
Not shown
- ASC30 Cohort 1: endpoint not reported
- ASC30 Cohort 2: endpoint not reported
- ASC30 Cohort 3: endpoint not reported
- Placebo Cohort 4: endpoint not reported